Kheir, A., Johannsdottir, B., Grönn-Weiss, A., Liu, L. L., Ullén, A., Laurell, A., … Harmenberg, U. (2025). Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab. Acta Oncologica, 64, 1355–1364. https://doi.org/10.2340/1651-226X.2025.44533